The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Clinical implementation of ctDNA monitoring for NSCLC
Aslaug Helland, MD, PhD, University of Oslo, Oslo, Norway, emphasizes the need for standardization in studies on circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in lung cancer, highlighting the importance of randomized trials to establish the value of these biomarkers. Current studies vary in methods, cut-offs, and findings, making it challenging to determine the reliability of individual studies and their overall value. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We need to standardize the methods. We need to know the value through randomized trials, more trials, more studies. Today we have had quite a lot of studies, but they use different methods, different cut-offs, and it’s not harmonized in any way, so it’s hard to know what kind of value the different studies have. The findings have also been diverging. So we need more studies, we need more knowledge, and preferably through random trials...
We need to standardize the methods. We need to know the value through randomized trials, more trials, more studies. Today we have had quite a lot of studies, but they use different methods, different cut-offs, and it’s not harmonized in any way, so it’s hard to know what kind of value the different studies have. The findings have also been diverging. So we need more studies, we need more knowledge, and preferably through random trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Funding – AstraZeneca (Inst); Bristol Myers Squibb (Inst); GlaxoSmithKline (Inst); Illumina (Inst); InCyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Ultimovacs (Inst)
